Echocardiography in Chronic Liver Disease: Systematic Review

Mota, Vitor Gomes; Filho, Brivaldo Markman

doi:10.5935/abc.20130047

Cited by 9 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, RV diastolic dysfunction was universally found in all studies that enrolled patients with CLD . In children with CLD secondary to hepatitis B, the isovolumic relaxation time was significantly increased, whereas the velocity of the early diastolic wave on tissue Doppler imaging was significantly decreased .…”

Section: Discussionmentioning

confidence: 93%

“…Pulmonary hypertension induces pathologic changes in the RV even in the absence of cirrhotic cardiomyopathy . Several studies found increased RV and RA dimensions, as well as increased RV free wall thickness, in patients with CLD . In these studies, however, patients with high pulmonary artery pressure were not excluded systematically.…”

Section: Discussionmentioning

confidence: 99%

“…17 Several studies found increased RV and RA dimensions, as well as increased RV free wall thickness, in patients with CLD. 9,18,19 In these studies, however, patients with high pulmonary artery pressure were not excluded systematically. In our study, we found that RV dimensions were similar to those of controls in patients with CLD and normal pulmonary artery pressure and pulmonary vascular resistance, thus suggesting that the changes in RV geometry are caused by PH rather than cirrhotic cardiomyopathy.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, RV diastolic dysfunction was universally found in all studies that enrolled patients with CLD. 9,11,18 In children with CLD secondary to hepatitis B, the isovolumic relaxation time was significantly increased, whereas the velocity of the early diastolic wave on tissue Doppler imaging was significantly decreased. 11 Karabulut et al 9 found increased RV free wall thickness, a reduced tricuspid E/A ratio and myocardial early diastolic wave velocity, and higher RV thickness in patients with CLD.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Morphologic and Functional Changes in Right‐Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure

Günay

Erdem

Güvenç

et al. 2017

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Morphologic and Functional Changes in Right‐Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure

Günay

Erdem

Güvenç

et al. 2017

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

“…On the other hand, CCM is characterized by a decrease in ventricular response to stress even though the patient presents normal or increased basal cardiac output. Systolic, diastolic, electrophysiological, structural, histological and biochemical modifications are noticed in CCM [10, 11, 12, 13]. …”

Section: Introductionmentioning

confidence: 99%

Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome

Mocarzel

Bicca

Jarske

et al. 2016

Case Rep Gastroenterol

View full text Add to dashboard Cite

Hepatorenal syndrome (HRS) is defined as a failure of renal function, potentially reversible, in patients with liver cirrhosis and ascites. Recently, a component of cardiomyopathy associated with HRS was described, but the use of positive inotropic medicine as part of the treatment of the acute phase has not been extensively evaluated. We report a second case in our hospital of a patient with HRS type I without previous heart disease, with secondary hemodynamic decompensation due to liver disease, in which the abnormalities in systolic function by speckle-tracking echocardiography were observed and could be reversed by the use of inotropes. After partial response to current therapies, the patient presented a clinical and laboratorial response with improvement of renal function after infusion of dobutamine. Clinical studies are needed for the therapy approach to HRS taking into account myocardial dysfunction as a major contributing factor for renal dysfunction.

show abstract

Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment

Miftode

Șerban

Timpau

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

The close connection and interaction between the cardiac and the liver functions are well-known, as cirrhotic cardiomyopathy is an important clinical entity which best describes the mutual pathogenical influence between these two organs. Due to the fact that cardiac dysfunction in patients with chronic hepatic disorders is oligosymptomatic or even asymptomatic, an early diagnosis represents a challenge for every physician. Syndecan-1—a transmembrane proteoglycan that exerts its functions mainly via its heparane sulfate chains—is a very promising biomarker, correlated not only with the degree of cardiac fibrosis but also with the severity of liver fibrosis. Many studies highlighted its role in the development of cardiac fibrosis or atherogenesis, being significantly correlated with the activity of angiotensin II. Multiple evidence revealed that syndecan-1 is also associated with tissue injury and may regulate inflammatory and regenerative responses, being considered a protective molecule that limits the inflammation and reduces cardiac remodelling and dysfunction after a myocardial infarction. Syndecan-1 may also be used as a reliable biomarker for the noninvasive assessment of liver fibrosis. Under various fibrogenetic conditions, shedding of syndecan's extracellular domain took place, becoming a soluble form that binds different growth factors and inhibits further fibrosis. This complex molecule is also involved in the lipid metabolism, by altering the clearance of cholesterol particles, and in chronic hepatitis, by enhancing the viral invasion of hepatocytes. Due to the growing interest in this biomarker, multiple studies aimed at revealing syndecan-1's potential benefits in the diagnosis and prognosis assessment in patients with heart failure or chronic liver disorders. In this review, we review the mechanisms by which syndecan-1 exerts its effects and the possible perspectives opened by its use as a dual cardio-hepatic biomarker.

show abstract

Echocardiography in Chronic Liver Disease: Systematic Review

Cited by 9 publications

References 26 publications

Morphologic and Functional Changes in Right‐Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure

Morphologic and Functional Changes in Right‐Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure

Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome

Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment

Contact Info

Product

Resources

About